Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study

Ruben D. Kowalyszyn, MD1; Luis E. Fein, MD2; Martin E. Richardet, MD3; Mirta S. Varela, MD4; Eduardo Ortiz, MD5; Cristian Micheri, MD6; Juan J. Zarba, MD7; Susana Kahl, MD8; Ezequiel Klimovsky, MD9; Andrea A. Federico, BS9; Jorge H. Cassini, MD10; Gustavo Cortese, MD11; and Nestor Lago, MD12

PURPOSE This study evaluated the efficacy, safety, and immunogenicity of biosimilar pegfilgrastim (PegFilBS) and originator pegfilgrastim (PegFilOR) in patients with stage 2-4 breast cancer.

METHODS This phase III randomized, multicenter, evaluator-blinded, noninferiority study recruited women with stage 2-4 breast cancer in Argentina who were scheduled to receive chemotherapy. Stratification was based on the breast cancer stage. The primary end point was the duration of severe neutropenia (DSN, noninferiority margin: 1 day) in the first chemotherapy cycle. Secondary end points assessed were incidence of severe neutropenia, grade 3 neutropenia, febrile neutropenia, infections, postchemotherapy hospitalization and duration, and the incidence of adverse drug reactions (ADRs).

RESULTS A total of 120 patients were randomly assigned to receive PegFilBS (58 patients) or PegFilOR (62 patients). Severe neutropenia occurred in 52 of 283 cycles (18.4%) for 27 patients who received PegFilBS and in 48 of 297 cycles (16.2%) for 20 patients who received PegFilOR (P = .48). During the first cycle, severe neutropenia occurred in 16 patients who received PegFilBS (DSN: 0.78 ± 1.53 days) and in 11 patients who received PegFilOR (DSN: 0.53 ± 1.25 days; 95% CI, −0.26 to 0.76 days). In the intention-to-treat analysis, the mean DSN values were 0.90 ± 1.79 days for the PegFilBS group and 0.50 ± 1.21 for the PegFilOR group (95% CI, −0.15 to 0.95 days). No significant differences were observed for the secondary efficacy end points. Three patients experienced seven ADRs in the PegFilBS group while 10 patients experienced 31 ADRs in the PegFilOR group. The most common ADR was myalgia.

CONCLUSION Relative to PegFilOR, PegFilBS provided noninferior efficacy outcomes in Argentinian women with stage 2-4 breast cancer who were treated using myelosuppressive chemotherapy.

JCO Global Oncol 8:e2100276. © 2022 by American Society of Clinical Oncology

INTRODUCTION

Neutropenia is common in patients with cancer who receive myelosuppressive chemotherapy and contributes to cancer-associated morbidity. Moreover, neutropenia is associated with an increased risk of infection, which can be life-threatening and requires aggressive treatment using intravenously administered antibiotics. Neutropenia-related infection often manifests as febrile neutropenia and can lead to hospitalization, morbidity, and mortality in up to 10% of patients.1

Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein that acts on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation, commitment, and some end-cell functions.2 Human G-CSF is a single polypeptide chain protein (174 amino acids) with O-glycosylation at a single threonine residue. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes, fibroblasts, and endothelial cells. Furthermore, G-CSF regulates neutrophil production within the bone marrow and affects neutrophil progenitor proliferation and differentiation.4 Moreover, G-CSF activates select end-cell functions, such as enhanced phagocytic ability, priming of the cellular metabolism associated with respiratory bursts,5 antibody-dependent killing, and increases in some cell surface antigen-associated functions. Various methods are used to produce recombinant forms
CONTEXT

Key Objective
Are the efficacy, safety, and immunogenicity results obtained with a proposed biosimilar pegfilgrastim similar to the results obtained with the originator pegfilgrastim in patients with stage 2-4 breast cancer? To the best of our knowledge, this is the first clinical trial to evaluate a biosimilar pegfilgrastim that was developed in this region.

Knowledge Generated
Duration of severe neutropenia in the first chemotherapy cycle was similar with the two drugs (0.78 ± 1.53 days and 0.53 ± 1.25 days; CI for the difference, −0.26 to 0.76 days for 1 day noninferiority margin). An equivalence analysis was conducted as a sensitivity analysis. For both per-protocol and intention-to-treat populations, the Schuirmann two one-sided test showed equivalence.

Relevance
These results may help improve access to biologic drugs in Latin America.

METHODS

Ethical Considerations
The study was conducted in accordance with the Declaration of Helsinki and the Council for Harmonization Good Clinical Practice Guidelines. The study protocol (ClinicalTrials.gov identifier: NCT03404752) was approved by the institutional ethics committee at each site. All patients provided written informed consent before enrollment.

Study Design
This randomized, multicenter, evaluator-blinded, non-inferiority, parallel group, controlled study was conducted at 12 sites in Argentina. The study was designed on the basis of the European Medical Association recommendations for biosimilar G-CSF products that were in effect when the study protocol was prepared and written. The study was not conducted as a double-blind study because of regulatory constraints; it is not possible to modify the original one to make it the same as the biosimilar. However, bias was avoided because at each site, only the pharmacist and physician/nurse in charge of drug administration were not blinded. All evaluators were blinded when evaluating the laboratory test results, clinical efficacy, safety end points, and the causality of adverse events (AEs). A safety monitoring committee performed two interim analyses.

of G-CSF. Filgrastim is one form, which is produced by Escherichia coli that expresses the human gene for G-CSF, and the product can be conjugated to monomethoxypolyethylene glycol (pegfilgrastim). This product has been approved by health authorities as prophylactic treatment to decrease the incidence of febrile neutropenia in patients with nonmyeloid malignancies who are receiving myelosuppressive anticancer drugs that are associated with a clinically significant incidence of febrile neutropenia. Some medical organizations have suggested that systematic use of hematopoietic growth factors, including G-CSF and pegfilgrastim, is not justified as prophylaxis for chemotherapy-induced neutropenia unless the risk of febrile neutropenia exceeds 20% or there are special circumstances. Regimens used to treat breast cancer in the adjuvant, neoadjuvant, or metastatic setting are associated with more than 20% risk of febrile neutropenia. In addition to the risk associated with the specific chemotherapy regimen and malignancy, additional risk factors need to be considered. For example, the risk of febrile neutropenia is increased among older patients (especially those who are ≥ 65 years), patients who have received previous chemotherapy or radiotherapy, patients with pre-existing neutropenia or tumor involvement in the bone marrow, and patients with pre-existing conditions (eg, neutropenia, infection/open wound, recent surgery, poor performance status, poor renal function, and liver dysfunction, especially elevated bilirubin concentrations). Biosimilars (or similar biotherapeutic products) are biotherapeutic agents that are considered similar in terms of quality, safety, and efficacy, relative to a currently licensed reference biotherapeutic product. Market approval of biosimilars may be granted after the patent for the reference product expires, and Latin America is currently undergoing a full consolidation of regulatory procedures for biosimilars. As the region moves toward a stronger biosimilar registration program, the status and strictness of its regulations are evolving and consolidating. A biosimilar form of pegfilgrastim (PegFilBS; Peg-Neutropine, Gema Biotech SAU, CABA, Argentina) has been developed in reference to the originator pegfilgrastim (PegFilOR; Roche, Chile). Analytical comparability and preclinical studies have shown that PegFilBS and PegFilOR are structurally similar and provide similar therapeutic results (Protocol). Therefore, this phase III study aimed to compare the efficacy, safety, and immunogenicity of PegFilBS and PegFilOR in patients who were receiving myelosuppressive chemotherapy for stage 2-4 breast cancer.
when the study reached 48 and 100 randomly assigned participants. Both analyses were blinded to the safety monitoring committee. The difference in the duration of severe neutropenia (DSN) during the first analysis was 0 day (CI 95%, –0.6 to 0.6; P = .500), and for the second interim analysis, it was 0.13 days (CI 95%, –0.13 to 0.39), and the safety results were similar for both arms. There were no formal stopping rules planned for the interim analyses.

**Patients**

Women were considered eligible if they were age 18–70 years, had stage 2–4 breast cancer, were scheduled to receive four or six cycles of taxane-containing chemotherapy at 3-week intervals, had an ECOG performance status of 0–2, had a life expectancy of > 6 months, and adequate bone marrow, renal, and hepatic functions. Targeted treatments using monoclonal antibodies were permitted in addition to the taxane-containing regimens. Sexually active premenopausal women were required to use an acceptable form of contraception, and fertile women were required to have monthly negative results from a serum pregnancy test while using the study drugs. A complete list of the inclusion and exclusion criteria is provided in the Protocol.

**Random Assignment**

Participants were enrolled at the study sites and randomly assigned 1:1 in blocks to receive either PegFilBS (Peg-Neutropine, GEMA BIOTECH S.A.U, Buenos Aires, Argentina) or PegFilOR (Roche). The sequence generated by the random assignment system was concealed until the treatments were assigned. Stratification was based on breast cancer stage, adjuvant chemotherapy, neoadjuvant chemotherapy, first-line chemotherapy for metastatic disease, and other lines of chemotherapy for metastatic disease.

**Treatments**

Unblinded physicians or nurses administered the treatments subcutaneously (dose: 6 mg) once per chemotherapy cycle for up to six cycles. All treatments were administered at 24-72 hours after completing the chemotherapy cycle.
Outcomes and End Points

The primary efficacy end point was the DSN (absolute neutrophil count: <500/mm³) in the first chemotherapy cycle. To evaluate the primary end point, neutrophil count was measured each day from day 5 to day 9 after chemotherapy, and when the patient developed severe neutropenia (SN) during the first cycle, the same schedule was performed on the following cycle. When the patient did not develop SN on the following cycles, neutrophil count was measured on days 5 and 7. The secondary efficacy end points were the incidences of severe neutropenia that was not associated with fever, grade 3 neutropenia (ANC: 500-1,000/mm³), febrile neutropenia across all cycles (ANC: <1,000/mm³ plus a single temperature of >38.3°C or a sustained temperature of >38°C for >1 hour), infection, requirement for intravenous anti-infection treatment, postchemotherapy hospitalization and duration, neutropenia-related hospitalization and duration, infection-related mortality, and ability to maintain the planned chemotherapy regimen during cycles 2-6 (≥80% of the planned dose and no dose ≥3d a sl a t e).

The safety end points included the incidences of serious and nonserious adverse drug reactions (ADRs), as well as patient withdrawal because of inability to tolerate the drug (systematically or at the injection site). Immunogenicity was evaluated on the basis of titers of neutralizing antibodies and binding antibodies to PegFilBS and PegFilOR, which were measured using validated surface plasmon resonance technology at baseline and on days 5 and 28 of the last chemotherapy cycle. The immunogenicity tests were performed at a Immunology Department-IDEHU Laboratory (Pharmacy and Biochemist School, Buenos Aires University).

Sample Size Calculation

The original pivotal study that supported the approval of PegFil used a fixed dose of 6 mg, which produced an average grade 4 neutropenia duration of 1.8 days (estimated standard deviation: 2.1 days). On the basis of those results and the width of the 95% CI around the difference in the median times for ANC recovery, a sample size of 120 patients (assuming 10% lost to follow-up) would be needed to provide 80% power with a one-sided α value of .05 to support a preliminary conclusion of noninferiority.16 Using 60 patients per treatment group, one-half the width of the 95% CI for the difference in the median DSN was estimated to be <1 day, which was defined as the noninferiority margin.

Statistical Analysis

The statistical analyses were performed using SPSS software (version 16.0, SPSS Inc, Chicago, IL), the Primer of Biostatistics (version 4.02, 1996), and a measurement worksheet for noninferiority studies (Digestive Unit, Hos-
The primary efficacy analyses were performed using a one-sided test of the difference in means, and the 95% CIs for these estimates were also calculated. The Schuirmann two one-sided test was used for the post hoc equivalence analysis. The null hypotheses of the Schuirmann one-sided double t tests indicate that bioinequivalence are rejected with a significance level of .05. The T-test for comparisons of proportions was used for the secondary end point analysis. The last observation carried forward approach was selected for missing data in the intention-to-treat (ITT) analysis. The safety parameters were reported using descriptive statistics. The secondary end points were not adjusted for multiplicity.

RESULTS

Patient Characteristics

The recruitment period started on July 21, 2015, and the last patient visit was enrolled on September 19, 2018. A total of 121 patients were randomly assigned, although one patient was not treated, to receive PegFilBS (58 patients) or PegFilOR (62 patients). Twenty-seven patients discontinued treatment (Fig 1, CONSORT), although discontinuations occurred after completing the first chemotherapy cycle. Thus, the primary end point could be evaluated for 117 patients.

The median age was 55.8 years, and the average body surface area was 1.71 m². All patients were Hispanic, and the two treatment groups had balanced baseline characteristics in terms of age, weight, body surface area, breast cancer stage, number of prior chemotherapy regimens, prior radiotherapy, chemotherapy regimen administered, and leukocyte count (Table 1).

Efficacy

In the per-protocol analysis, 117 patients were evaluated. One patient allocated to PegFilBS who did not receive the allocated intervention and three patients with protocol deviations (two patients recruited violating an inclusion or exclusion criterion and one patient who received PegFilOR instead of receiving PegFilBS) were excluded. Severe neutropenia occurred in 52 of 283 cycles (18.4%) for 27 patients who received PegFilBS and in 48 of 297 cycles (16.2%) for 20 patients who received PegFilOR ($P = .48$). During the first chemotherapy cycle, severe neutropenia

![FIG 2. Primary efficacy end point duration of severe neutropenia, per-protocol, and intention-to-treat analysis.](image-url)

### TABLE 2. Efficacy Secondary End Points Results Per Treatment Arm

| Secondary End Points Efficacy                                      | PegFilBS (N = 58), No. (%) | PegFilOR (N = 59), No. (%) | Difference, % | $P$   |
|-------------------------------------------------------------------|----------------------------|----------------------------|---------------|-------|
| Incidence of severe neutropenia not associated with fever across the cycles | 18 (31.0)                  | 24 (40.7)                  | −9.7          | .2741 |
| Grade 3 neutropenia across the cycles                             | 28 (49.3)                  | 20 (33.9)                  | 15.4          | .0910 |
| Incidence of febrile neutropenia                                  | 2 (3.4)                    | 1 (1.7)                    | 1.7           | .5592 |
| Incidence of ANC < 500/mm³ and body temperature of > 38.3°C      | 1 (1.7)                    | 1 (1.7)                    | 0.0           | —     |
| Incidence of fever                                                | 2 (3.4)                    | 1 (1.7)                    | 1.7           | .5592 |
| Incidence of infections                                           | 3 (5.2)                    | 1 (1.7)                    | 3.5           | .2987 |
| Incidence of postchemotherapy hospitalization                     | 1 (1.7)                    | 2 (3.4)                    | −1.7          | .5603 |
| Mortality because of infection                                     | 1 (1.7)                    | 0                          | 1.7           | .3145 |

NOTE. Hypothesis test: t-test for comparisons of proportions.

Abbreviations: ANC, absolute neutrophils count; PegFilBS, biosimilar pegfilgrastim; PegFilOR, originator pegfilgrastim.
**TABLE 3. Adverse Drug Reactions Results Per Treatment Arm**

| ADRs                          | PegFilBS (N = 58) | PegFilOR (N = 62) |
|-------------------------------|-------------------|-------------------|
| **Patients, No. (%)**         | 3 (5.2)           | 10 (16.1)         |
| **Reactions, No.**            | 7                 | 31                |
| **Arthralgia**                |                   |                   |
| Patients, No. (%)             | 0                 | 2 (3.2)           |
| Reactions, No.                | 2                 |                   |
| **Asthenia**                  |                   |                   |
| Patients, No. (%)             | 0                 | 1 (1.6)           |
| Reactions, No.                | 2                 |                   |
| **Bone pain**                 |                   |                   |
| Patients, No. (%)             | 0                 | 2 (3.2)           |
| Reactions, No.                | 2                 |                   |
| **Myalgias**                  |                   |                   |
| Patients, No. (%)             | 2 (3.4)           | 7 (11.3)          |
| Reactions, No.                | 6                 | 25                |
| **Gastroesophageal reflux disease** |          |                   |
| Patients, No. (%)             | 1 (1.7)           | 0                 |
| Reactions, No.                | 1                 |                   |

**Abbreviations:** ADR, adverse drug reaction; PegFilBS, biosimilar pegfilgrastim; PegFilOR, originator pegfilgrastim.

**Adverse drug reactions.** Three patients who received PegFilBS experienced seven ADRs while 10 patients who received PegFilOR experienced 31 ADRs. The most common ADR was myalgia, and other ADRs included arthralgia, asthenia, bone pain, and gastroesophageal reflux disease. Only one patient who received PegFilBS reported mild pain at the injection site during the fifth treatment cycle (Table 3).

**Immunogenicity.** Negative results regarding immunogenicity were observed for all 101 patients who underwent testing on day 28 after the last dose of PegFilBS or PegFilOR.

**DISCUSSION**

Two filgrastim biosimilars have been developed, studied, and approved in Latin America. However, to the best of our knowledge, this is the first clinical trial to evaluate a PegFilBS that was developed in this region. The PegFilBS developed by GEMA BIOTECH S.A.U. is the first to be approved in Latin America for preventing febrile neutropenia in patients who are receiving myelosuppressive chemotherapy. Since 2011, Argentina has enacted specific local regulations regarding the use of biosimilars, which can require comparability exercises and nonclinical data, with or without clinical data, depending on the specific product.

This noninferiority trial revealed that, during the first chemotherapy cycle, the mean DSN value was noninferior for patients who received PegFilBS (v PegFilOR) during treatment for stage 2-4 breast cancer. The noninferiority margin for DSN was defined as 1 day, which is similar to the margin used in other PegFilBS trials that aimed to support regulatory approval from the European Medical Association. Although regulatory authorities recommend equivalence trials, noninferiority trials may be performed if they have been previously justified. This is because the biosimilar product may actually provide a superior result or an increase in ADRs, although this is not probable for pegfilgrastim. Our results revealed similar safety profiles for PegFilBS and PegFilOR, with only expected AEs and SAEs, and no newly discovered AEs.
Furthermore, the immunogenicity results seem to indicate that PegFilBS was not associated with an increased likelihood of developing neutralizing antibodies and/or binding antibodies (v PegFilOR).

These findings, especially regarding safety, may be limited by the small sample size, although this did not seem to affect the efficacy of PegFilBS. In addition, we only enrolled Argentinian women, although it is important to note that the Argentinian population includes a mixture of European immigrants, Native Americans, and individuals of mixed descent. Furthermore, our study population is slightly different than in other Latin American countries; however, we are not aware of any data that indicate filgrastim/pegfilgrastim provides variable therapeutic effects or AEs in different ethnic populations.

In conclusion, this trial revealed that, relative to PegFilOR, PegFilBS (Peg-Neutropine) was associated with noninferior efficacy and safety outcomes in women who were receiving myelosuppressive chemotherapy for stage 2-4 breast cancer. These results suggest that third-world countries are capable of developing and marketing biosimilar products, which may help dramatically increase the currently limited access to biological drugs among our patients, especially relative to patients in more developed parts of the world.

Affiliations

1. Centro De Investigaciones Clinicas Clinica Viedma S A, Viedma, Argentina
2. Instituto Oncológico de Rosario, Rosario, Argentina
3. Sanatorio Aconcagua, Córdoba, Argentina
4. COIBA, Berazategui, Buenos Aires, Argentina
5. Instituto de Oncología de Córdoba, Córdoba, Argentina
6. Instituto de Oncología de Córdoba, Rosario, Santa Fé, Argentina
7. Hospital Aeronautico Central, CABA, Argentina
8. Hospital de Clínicas “José de San Martín,” CABA, Argentina
9. Gema Biotech SAU, CABA, Argentina

Corresponding Author

Ezequiel Klimovsky, MD, Arazo 274, PC 1414, CABA, Argentina; e-mail: eklimovsky@quid-consulting.com.

Prior Presentation

Presented as an abstract and poster at the ASCO meeting 2019 (suppl; abstr 3113).

Support

Supported by Gema Biotech SAU.

Data Sharing Statement

A data sharing statement provided by the authors is available with this article at DOI https://doi.org/10.1200/jco.21.00276. Other data will be available for interested people through Clinical trials.gov.

Author Contributions

Conception and Design: Luis E. Fein, Ezequiel Klimovsky, Jorge H. Cassini, Gustavo Cortese, Nestor Lago
Collection and assembly of data: Ruben D. Kowalszyn, Martin E. Richardet, Mirta S. Varela, Eduardo Ortiz, Cristian Micheri, Juan J. Zarba, Susana Kahl
Data analysis and interpretation: Ruben D. Kowalszyn, Luis E. Fein, Ezequiel Klimovsky, Andrea A. Federico, Nestor Lago
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

Authors’ Disclosures of Potential Conflicts of Interest

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Ruben D. Kowalszyn
Consulting or Advisory Role: BMS Argentina, MSD Oncology, Astellas Pharma, Merck Sereno
Speakers’ Bureau: BMS Argentina, Novartis
Research Funding: BMS, MSD Oncology, Novartis, Roche, Astellas Pharma

Luis E. Fein
Consulting or Advisory Role: Novartis, Pfizer, AstraZeneca/Merck
Eduardo Ortiz
Consulting or Advisory Role: Boehringer Ingelheim, AstraZeneca, Pfizer, Roche, Bristol Myers Squibb
Speakers’ Bureau: Bristol Myers Squibb
Research Funding: Bristol Myers Squibb, Merck Sharp & Dohme, Janssen, Amgen, Astellas Pharma, Roche, Novartis/Pfizer
Travel, Accommodations, Expenses: Bristol Myers Squibb, Pfizer

Juan J. Zarba
Consulting or Advisory Role: Pfizer/EMD Serono, Pfizer, Astellas Pharma
Research Funding: MSD Oncology, Lilly, Exelixis, Astellas Pharma
Expert Testimony: Lilly
Travel, Accommodations, Expenses: Roche, Pfizer

Ezequiel Klimovsky
Other Relationship: Gema Biotech SAU, AbbVie, La Roche-Posay, Roemmers, Merz GmbH

Nestor Lago
Employment: Gemabiotech

No other potential conflicts of interest were reported.

Acknowledgment

We would like to thank Editage (www.editage.com) for English language editing.
REFERENCES

1. Kuderer NM, Dale DC, Crawford J, et al: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-2266, 2006
2. Committee for Medicinal Products for Human Use (CHMP): Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. Guidance on Similar Medicinal Products Containing Recombinant Granulocyte-Colony Stimulating Factor. EMEA/CHMP/BWP/31329/2005. London UK, 2006
3. Welte K, Bonilla MA, Gillo AP, et al: Recombinant human G-CSF: Effects on hematopoiesis in normal and cyclophosphamide treated primates. J Exp Med 165:941-948, 1987
4. Souza LM, Boone TC, Gabriole J, et al: Recombinant human granulocyte colony stimulating factor: Effects on normal and leukemic myeloid cells. Science 232:63-65, 1986
5. Weisbart RH, Kacena A, Schuh A, et al: GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 332:647-648, 1988
6. Kitagawa S, Yuo A, Souza LM, et al: Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by chemotactic peptide. Biochem Biophys Res Commun 144:1143-1146, 1987
7. 2006 update of ASCO practice guideline recommendations for the use of white blood cell growth factors: Guideline summary. J Clin Oncol 24:3187-3205, 2006
8. Crawford J, Caserta C, Roila F, et al: Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol 21:v248-v251, 2010 (suppl 5)
9. Crawford J, Allen J, Armitage J, et al: NCCN Guidelines Version 1.2011 Myeloid Growth Factors. National Comprehensive Cancer Network, Inc, 2011
10. Younis T, Rayson D, Thompson K: Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: A systematic review and meta-analysis. Support Care Cancer 20:2523-2530, 2012
11. Do T, Medhekar R, Bhat R, et al: The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: A meta-analysis. Breast Cancer Res Treat 153:591-597, 2015
12. Weycker D, Li X, Barron R, et al: Importance of risk factors for febrile neutropenia among patients receiving chemotherapy regimens not classified as high-risk in guidelines for myeloid growth factor use. J Natl Compr Canc Netw 13:979-986, 2015
13. Lyman GH, Dale DC, Legg JC, et al: Assessing patients' risk of febrile neutropenia: Is there a correlation between physician-assessed risk and model-predicted risk? Cancer Med 4:1153-1160, 2015
14. World Health Organization: WHO Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Geneva, Switzerland, World Health Organization, 2009
15. Lizaraga A, Mysler E: Similar and mimics: Latin America biosimilar regulations. Int J Rheum Dis 22:6-8, 2019
16. Tajar D: Estudios de no inferioridad (equivalencia). http://www.gedic.com.ar/publicacion_lecturascomp.shtml
17. Hegg R, Mattar A, Matos-Neto IM, et al: A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients. Clinics 71:586-592, 2016
18. Mendoza-Macedo K, Romero-Díaz AJ, Miranda-Hernández MP, et al: Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America. Electron J Biotechnol 19:63-69, 2016
19. ANMAT Resolution 7729/11. Regulation for Biosimilar Products. ANMAT, Ministry of Health, Buenos Aires, Argentina, 2011
20. Committee for Medicinal Products for Human Use: Assessment Report Fulphila. Procedure No. EMEA/H/C/004915/0000 EMA. London, UK, 2018
21. Committee for Medicinal Products for Human Use: Assessment Report Ziextenzo Procedure No. EMEA/H/C/004802/0000 EMA/706001/2018. London, UK, 2018
22. Committee for Medicinal Products for Human Use (CHMP): Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-clinical and Clinical Issues. Amsterdam, the Netherlands, European Medicines Agency, 2014
23. US Department of Health and Human Services, Food and Drugs Administration: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Silver Spring, MD, 2015